Janus Kinase 2 (JAK2)

[Edit]

JTK10; Tyrosine-protein kinase JAK2

Janus Kinase 2 (JAK2)
Janus kinase 2 is a protein that has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family (IL-3R, IL-5R and GM-CSF-R), the gp130 receptor family (e.g. IL-6R), and the single chain receptors (e.g. Epo-R, Tpo-R, GH-R, PRL-R). JAK2 signaling is activated downstream from the prolactin receptor. JAK2 gene fusions with the TEL(ETV6) (TEL-JAK2) and PCM1 genes have been found in leukemia patients. Further, mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, and other myeloproliferative disorders. This mutation, a change of valine to phenylalanine at the 617 position, appears to render hematopoietic cells more sensitive to growth factors such as erythropoietin and thrombopoietin.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPF494Hu01 Recombinant Janus Kinase 2 (JAK2) Positive Control; Immunogen; SDS-PAGE; WB.
APF494Hu01 Active Janus Kinase 2 (JAK2) Cell culture; Activity Assays.
Antibodies PAF494Hu01 Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC/IF
LAF494Hu71 Biotin-Linked Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC.
Assay Kits SEF494Hu ELISA Kit for Janus Kinase 2 (JAK2) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPF494Mu01 Recombinant Janus Kinase 2 (JAK2) Positive Control; Immunogen; SDS-PAGE; WB.
RPF494Mu02 Recombinant Janus Kinase 2 (JAK2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAF494Mu01 Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC; IP.
PAF494Mu02 Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC; IP.
LAF494Mu71 Biotin-Linked Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC.
Assay Kits SEF494Mu ELISA Kit for Janus Kinase 2 (JAK2) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPF494Ra01 Recombinant Janus Kinase 2 (JAK2) Positive Control; Immunogen; SDS-PAGE; WB.
RPF494Ra02 Recombinant Janus Kinase 2 (JAK2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAF494Ra01 Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC; IP.
PAF494Ra02 Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC; IP.
LAF494Ra71 Biotin-Linked Polyclonal Antibody to Janus Kinase 2 (JAK2) WB; IHC; ICC.
Assay Kits SEF494Ra ELISA Kit for Janus Kinase 2 (JAK2) Enzyme-linked immunosorbent assay for Antigen Detection.
  1. "Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue."Biochem. Biophys. Res. Commun. 246:627-633(1998) [PubMed] [Europe PMC] [Abstract]
  2. "Cloning and characterization of the human homolog of mouse Jak2."Blood 91:844-851(1998) [PubMed] [Europe PMC] [Abstract]
  3. "Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia."Blood 90:2535-2540(1997) [PubMed] [Europe PMC] [Abstract]
  4. "DNA sequence and analysis of human chromosome 9." Nature 429:369-374(2004) [PubMed] [Europe PMC] [Abstract]
  5. "The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity."J. Biol. Chem. 274:31531-31542(1999) [PubMed] [Europe PMC] [Abstract]
  6. "STAM2, a new member of the STAM family, binding to the Janus kinases."FEBS Lett. 477:55-61(2000) [PubMed] [Europe PMC] [Abstract]
  7. "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R." J. Immunol. 168:5699-5708(2002) [PubMed] [Europe PMC] [Abstract]
  8. "The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2." Cancer Res. 65:2662-2667(2005) [PubMed] [Europe PMC] [Abstract]
  9. "PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation."Leukemia 19:1692-1696(2005) [PubMed] [Europe PMC] [Abstract]
  10. "The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene."Oncogene 24:7248-7252(2005) [PubMed] [Europe PMC] [Abstract]
  11. "A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia."Haematologica 91:817-820(2006) [PubMed] [Europe PMC] [Abstract]
  12. "A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma."Leukemia 20:536-537(2006) [PubMed] [Europe PMC] [Abstract]
  13. "JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin."Nature 461:819-822(2009) [PubMed] [Europe PMC] [Abstract]
  14. "Heme controls the regulation of protein tyrosine kinases Jak2 and Src."Biochem. Biophys. Res. Commun. 403:30-35(2010) [PubMed] [Europe PMC] [Abstract]
  15. "The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure."Nat. Med. 16:183-190(2010) [PubMed] [Europe PMC] [Abstract]
  16. "Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control."Oncogene 30:3502-3512(2011) [PubMed] [Europe PMC] [Abstract]
  17. "Jak2 tyrosine kinase: a mediator of both housekeeping and ligand-dependent gene expression?"Cell Biochem. Biophys. 44:213-222(2006) [PubMed] [Europe PMC] [Abstract]
  18. "Janus kinases in immune cell signaling."Immunol. Rev. 228:273-287(2009) [PubMed] [Europe PMC] [Abstract]
  19. "The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor."Blood 107:176-183(2006) [PubMed] [Europe PMC] [Abstract]
  20. "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders."Lancet 365:1054-1061(2005) [PubMed] [Europe PMC] [Abstract]
  21. ErratumLancet 366:122-122(2005)
  22. "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study."Lancet 366:1945-1953(2005) [PubMed] [Europe PMC] [Abstract]
  23. "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera."Nature 434:1144-1148(2005) [PubMed] [Europe PMC] [Abstract]
  24. "A gain-of-function mutation of JAK2 in myeloproliferative disorders."N. Engl. J. Med. 352:1779-1790(2005) [PubMed] [Europe PMC] [Abstract]
  25. "Case records of the Massachusetts General Hospital. Case 15-2006: a 46-year-old woman with sudden onset of abdominal distention."N. Engl. J. Med. 354:2166-2175(2006) [PubMed] [Europe PMC] [Abstract]
  26. "The JAK2 V617F mutation in de novo acute myelogenous leukemias."Oncogene 25:1434-1436(2006) [PubMed] [Europe PMC] [Abstract]
  27. "The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation."Proc. Natl. Acad. Sci. U.S.A. 103:6224-6229(2006) [PubMed] [Europe PMC] [Abstract]
  28. "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis."N. Engl. J. Med. 356:459-468(2007) [PubMed] [Europe PMC] [Abstract]
  29. "Patterns of somatic mutation in human cancer genomes." Nature 446:153-158(2007) [PubMed] [Europe PMC] [Abstract]
  30. "Germline JAK2 mutation in a family with hereditary thrombocytosis."N. Engl. J. Med. 366:967-969(2012) [PubMed] [Europe PMC] [Abstract]